AbbVie Inc. $ABBV Stock Bought by Profund Advisors LLC

Profund Advisors LLC boosted its stake in AbbVie Inc. (NYSE:ABBV) by 8.6% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 28,417 shares of the company’s stock after purchasing an additional 2,249 shares during the quarter. Profund Advisors LLC’s holdings in AbbVie were worth $7,434,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of ABBV. Corient Private Wealth LP purchased a new position in shares of AbbVie in the 2nd quarter valued at $559,736,000. Legal & General Group Plc purchased a new stake in AbbVie in the second quarter valued at approximately $2,905,952,000. Jupiter Topco LLC acquired a new stake in AbbVie in the second quarter valued at approximately $1,560,354,000. Canada Pension Plan Investment Board acquired a new stake in shares of AbbVie during the second quarter worth about $817,473,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of AbbVie during the 2nd quarter worth $655,268,000. Institutional investors own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth

ABBV has been the subject of several research analyst reports. The Goldman Sachs Group upped their price target on AbbVie from $258.00 to $294.00 and gave the stock a “neutral” rating in a research note on Friday, October 23rd. Royal Bank Of Canada reiterated an “outperform” rating and set a $280.00 price objective on shares of AbbVie in a research report on Tuesday, October 13th. JPMorgan Chase & Co. lifted their target price on shares of AbbVie from $285.00 to $300.00 and gave the company an “overweight” rating in a research note on Thursday, October 8th. Bank of America reissued a “buy” rating on shares of AbbVie in a research report on Tuesday, September 8th. Finally, Wolfe Research upgraded AbbVie from a “peer perform” rating to an “outperform” rating and upped their target price for the company from $235.00 to $300.00 in a research note on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and a consensus price target of $279.86.

AbbVie Stock Performance

Shares of ABBV opened at $294.80 on Friday. The firm’s 50-day simple moving average is $269.35 and its 200 day simple moving average is $237.23. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $298.74. The firm has a market cap of $520.85 billion, a P/E ratio of 50.74, a price-to-earnings-growth ratio of 1.35 and a beta of 0.24.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.73 by $0.09. The business had revenue of $17.40 billion during the quarter, compared to analyst estimates of $17.32 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. AbbVie’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the company earned $1.86 EPS. As a group, equities analysts forecast that AbbVie Inc. will post 13.92 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.3%. AbbVie’s dividend payout ratio is currently 195.48%.

Insider Buying and Selling

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.06% of the stock is currently owned by insiders.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q3 results beat expectations. Adjusted earnings per share were $3.82 versus the $3.73 analyst consensus, while revenue rose 10.3% year over year to $17.404 billion, ahead of the $17.32 billion estimate. Adjusted EPS more than doubled from the prior-year quarter. AbbVie Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: Immunology and neuroscience provided strong momentum. Skyrizi generated $5.776 billion in revenue and Rinvoq produced $2.706 billion, helping immunology revenue increase 16.3%. Neuroscience revenue climbed 19.4%, led by Vraylar, therapeutic Botox, Ubrelvy and Qulipta. AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views
• Positive Sentiment: Management raised guidance and its dividend. AbbVie increased its 2026 adjusted EPS outlook to $13.95–$13.99 from $13.76–$13.96, despite including $0.69 per share of year-to-date acquired in-process research and development and milestone expenses. The company also announced a 5.2% dividend increase beginning with the February 2027 payment. AbbVie Raises FY26 Adjusted EPS Outlook and Boosts Dividend
• Positive Sentiment: Pipeline expansion supports longer-term confidence. AbbVie completed its acquisition of Apogee Therapeutics, strengthening its immunology pipeline, while Qulipta also outperformed topiramate in a Phase 3 migraine-prevention study. AbbVie QULIPTA Phase 3 Migraine Prevention Trial
• Negative Sentiment: Investors remain focused on valuation and concentration risks. Humira revenue fell 31.2% to $683 million, while aesthetics revenue declined 1.4%. After a substantial multiyear rally and trading near its 52-week high, analysts question whether additional valuation expansion is justified and how effectively AbbVie can sustain growth beyond Skyrizi and Rinvoq. Skyrizi and Rinvoq Dominate AbbVie Q3

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.